BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Melphalan delivered via Delcath's Chemosat system: Phase II data

Top-line data from 5 patients with hepatocellular carcinoma (HCC) and 4 patients with cholangiocarcinoma in the hepatobiliary cohort of an open-label, U.S. Phase II trial showed that melphalan delivered via Delcath's Chemosat system for the regional delivery of the drug to the liver followed by venous hemofiltration led to "positive efficacy signals" in both groups of tumor types. Details were not disclosed, but the company said responses...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >